12:00 AM
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xartemis XR oxycodone/acetaminophen regulatory update

Mallinckrodt said FDA extended the PDUFA date by 3 months for an NDA from the company for Xartemis XR oxycodone/acetaminophen extended-release tablets to manage moderate to severe acute pain where the use of an opioid analgesic is appropriate. The company did...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >